Respiratory syncytial virus-associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure

Ann R Falsey, Edward E Walsh, Mark T Esser, Kathryn Shoemaker, Li Yu, M Pam Griffin, Ann R Falsey, Edward E Walsh, Mark T Esser, Kathryn Shoemaker, Li Yu, M Pam Griffin

Abstract

Background: Respiratory syncytial virus (RSV) is recognized as a serious pathogen in people with chronic cardiopulmonary conditions. Immunoprophylaxis might be considered for adults at high-risk for frequent and severe RSV infection. Thus, we studied the incidence of RSV-related medically attended acute respiratory illness (MARI) in adults with severe chronic obstructive pulmonary disease (COPD) and/or congestive heart failure (CHF).

Methods: Subjects ≥50 years of age with Gold Class III/IV COPD and/or American Heart Association class III/IV CHF and exposure to children ≥once per month were recruited. Subjects were evaluated over 1.5 to 2.5 years for RSV-associated MARI, defined as polymerase chain reaction (PCR) and/or seroresponse.

Results: Four hundred forty-five subjects were enrolled between October 2011 and May 2012. Overall, 99 RSV infections were documented by PCR or serology for a cumulative incidence of 22.2%. Of these, 42 (9.4%) subjects had protocol-specified RSV-MARI for an incidence of 4.68/100 patient-seasons. All-cause MARI was common (63.85/100 patient-seasons) with rhinovirus most commonly identified.

Conclusion: RSV infection was common in adults with severe COPD and/or advanced CHF. Given the severity of underlying cardiopulmonary diseases in the study population, most illnesses were surprisingly mild. Thus, active immunization rather than passive immunoprophylaxis with monoclonal antibodies may be a more cost-effective strategy.

Keywords: disease control; epidemiology; immunoprophylaxis; respiratory syncytial virus (RSV); seasonal incidence; virus classification.

© 2018 Wiley Periodicals, Inc.

Figures

Figure 1
Figure 1
Disposition of subjects enrolled in the trial
Figure 2
Figure 2
Cases of RSV‐MARI per 100 person‐years distributed by preseason antibody titers. Antibody titers against F, N, Ga, and Gb are divided into quartiles with quartile 1 representing subjects with titers in the lowest 25th percentile and subjects in quartile 4 with the highest titers. In season 2 (gray bars), 21 subjects experienced RSV‐MARI of whom 20 had preseason serology and in season 3 (black bars), 9 subjects had RSV‐MARI of whom 8 had preseason serum. MARI, medically attended acute respiratory illness; RSV, respiratory syncytial virus
Figure 3
Figure 3
The positive rate for respiratory viruses detected by PCR during scheduled (A) and illness (B) visits. FLU A, influenza A; FLU B, influenza B; HMPV, human metapneumovirus; HRV, rhinovirus; PIV, Parainfluenza viruses; RSV, respiratory syncytial virus

References

    1. Hall CB, Simőes EAF, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:39‐57.
    1. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high‐risk adults. N Engl J Med. 2005;352(17):1749‐1759.
    1. Widmer K, Zhu Y, Williams JV, Griffin MR, Edwards KM, Talbot HK. Rates of hospitalizations for respiratory syncytial virus, human metapneumovirus, and influenza virus in older adults. J Infect Dis. 2012;206(1):56‐62.
    1. Thompson WW. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289(2):179‐186.
    1. Sundaram ME, Meece JK, Sifakis F, Gasser RA, Jr. , Belongia EA. Medically attended respiratory syncytial virus infections in adults aged >/=50 years: clinical characteristics and outcomes. Clin Infect Dis. 2014;58(3):342‐349.
    1. Walsh EE, Peterson DR, Falsey AR. Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis. 2004;189(2):233‐238.
    1. Lee N, Lui GCY, Wong KT, et al. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis. 2013;57(8):1069‐1077.
    1. Greenberg SB, Allen M, Wilson J, Atmar RL. Respiratory viral infections in adults with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;162(1):167‐173.
    1. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta‐analysis. J Glob Health. 2015;5(2):020415.
    1. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol. 2011;8(1):30‐41.
    1. Datta S, Walsh EE, Peterson DR, Falsey AR. Can analysis of routine viral testing provide accurate estimates of respiratory syncytial virus disease burden in adults? J Infect Dis. 2017;215(11):1706‐1710.
    1. The IMpact‐RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high‐risk infants. Pediatrics. 1998;102(3):531‐537.
    1. Pierce VM, Hodinka RL. Comparison of the GenMark Diagnostics eSensor respiratory viral panel to real‐time PCR for detection of respiratory viruses in children. J Clin Microbiol. 2012;50(11):3458‐3465.
    1. Fry AM, Chittaganpitch M, Baggett HC, et al. The burden of hospitalized lower respiratory tract infection due to respiratory syncytial virus in rural Thailand. PLoS One. 2010;5(11):e15098.
    1. Chu M, Parhy B, Park S, et al. Development and pilot study of a dual‐target RSV assay to detect and subtype respiratory syncytial virus in nasal swab samples. In: Proceedings from the Molecular Medicine Tri‐Conference; March 7, 2016; San Francisco, CA.
    1. Maifeld SV, Ro B, Mok H, et al. Development of electrochemiluminescent serology assays to measure the humoral response to antigens of respiratory syncytial virus. PLoS One. 2016;11(4):e0153019.
    1. Malloy AMW, Falsey AR, Ruckwardt TJ. Consequences of immature and senescent immune responses for infection with respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:211‐231.
    1. Mullooly JP, Bridges CB, Thompson WW, et al. Influenza‐ and RSV‐associated hospitalizations among adults. Vaccine. 2007;25(5):846‐855.
    1. Mehta J, Walsh EE, Mahadevia PJ, Falsey AR. Risk factors for respiratory syncytial virus illness among patients with chronic obstructive pulmonary disease. COPD. 2013;10(3):293‐299.
    1. Griffin MR, Coffey CS, Neuzil KM, Mitchel EF, Jr. , Wright PF, Edwards KM. Winter viruses: influenza‐ and respiratory syncytial virus‐related morbidity in chronic lung disease. Arch Intern Med. 2002;162(11):1229‐1236.
    1. Falsey AR, Walsh EE, Capellan J, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (RSV) vaccines—nonadjuvanted vaccine or vaccine adjuvanted with alum—given concomitantly with influenza vaccine to high‐risk elderly individuals. J Infect Dis. 2008;198(9):1317‐1326.
    1. Falloon J, Yu J, Esser MT, et al. An adjuvanted, postfusion F protein‐based vaccine did not prevent respiratory syncytial virus illness in older adults. J Infect Dis. 2017;216:1362‐1370.
    1. Walsh EE, Falsey AR. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis. 2004;190(2):373‐378.
    1. Falsey AR, Formica MA, Walsh EE. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription‐PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol. 2002;40(3):817‐820.
    1. Talbot HK, Falsey AR. The diagnosis of viral respiratory disease in older adults. Clin Infect Dis. 2010;50(5):747‐751.
    1. Branche AR, Walsh EE, Formica MA, Falsey AR. Detection of respiratory viruses in sputum from adults by use of automated multiplex PCR. J Clin Microbiol. 2014;52(10):3590‐3596.
    1. Greenberg S. Update on human rhinovirus and coronavirus infections. Semin Respir Crit Care Med. 2016;37(4):555‐571.
    1. Kurai D, Saraya T, Ishii H, Takizawa H. Virus‐induced exacerbations in asthma and COPD. Front Microbiol. 2013;4:293.
    1. Seemungal T, Harper‐Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618‐1623.
    1. Wilkinson TMA, Aris E, Bourne S, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72(10):919‐927.
    1. Walsh EE, Shin JH, Falsey AR. Clinical impact of human coronaviruses 229E and OC43 infection in diverse adult populations. J Infect Dis. 2013;208(10):1634‐1642.
    1. Gorse GJ, O’connor TZ, Hall SL, Vitale JN, Nichol KL. Human coronavirus and acute respiratory illness in older adults with chronic obstructive pulmonary disease. J Infect Dis. 2009;199(6):847‐857.
    1. Walsh EE, Peterson DR, Kalkanoglu AE, Lee FEH, Falsey AR. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J Infect Dis. 2013;207(9):1424‐1432.
    1. Falsey AR, Formica MA, Walsh EE. Yield of sputum for viral detection by reverse transcriptase PCR in adults hospitalized with respiratory illness. J Clin Microbiol. 2012;50(1):21‐24.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren